Lactate promotes glutamine uptake and metabolism in oxidative cancer cells. Issue 1 (2nd January 2016)

• Record Type: Journal Article
• Authors: Pérez-Escuredo, Jhudit; Dadhich, Rajesh K; Dhup, Suveera; Cacace, Andrea; Van Hée, Vincent F; De Saedeleer, Christophe J; Sboarina, Martina; Rodriguez, Fabien; Fontenille, Marie-Joséphine; Brisson, Lucie; Porporato, Paolo E; Sonveaux, Pierre
• Is Part Of: Cell cycle. Volume 15:Issue 1(2016)
• Page Start: 72
• Page End: 83
• Publication Date: 2016-01-02
• Subjects: Cancer -- c-Myc -- Glutamine -- glutaminolysis -- hypoxia-inducible factor-2 (HIF-2) -- Hypoxia-inducible factor (HIF) -- lactate signaling -- monocarboxylate transporter 1 (MCT1) -- Tumor metabolism; Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2015.1120930
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: Oxygenated cancer cells have a high metabolic plasticity as they can use glucose, glutamine and lactate as main substrates to support their bioenergetic and biosynthetic activities. Metabolic optimization requires integration. While glycolysis and glutaminolysis can cooperate to support cellular proliferation, oxidative lactate metabolism opposes glycolysis in oxidative cancer cells engaged in a symbiotic relation with their hypoxic/glycolytic neighbors. However, little is known concerning the relationship between oxidative lactate metabolism and glutamine metabolism. Using SiHa and HeLa human cancer cells, this study reports that intracellular lactate signaling promotes glutamine uptake and metabolism in oxidative cancer cells. It depends on the uptake of extracellular lactate by monocarboxylate transporter 1 (MCT1). Lactate first stabilizes hypoxia-inducible factor-2α (HIF-2α), and HIF-2α then transactivates c-Myc in a pathway that mimics a response to hypoxia. Consequently, lactate-induced c-Myc activation triggers the expression of glutamine transporter ASCT2 and of glutaminase 1 (GLS1), resulting in improved glutamine uptake and catabolism. Elucidation of this metabolic dependence could be of therapeutic interest. First, inhibitors of lactate uptake targeting MCT1 are currently entering clinical trials. They have the potential to indirectly repress glutaminolysis. Second, in oxidative cancer cells, resistance to glutaminolysis inhibition could arise from compensation by oxidative lactate metabolism and increased lactate signaling.